Rheumatoid arthritis trial

Risk increases with age and symptoms tend to worsen over time. Wear and tear, underlying conditions, and viral or bacterial infections can all contribute to arthritis. Rheumatoid arthritis in particular is associated with a faulty autoimmune response. This causes the immune system to attack the joint linings. A rheumatoid arthritis diagnosis depends on distinguishing it from other forms of arthritis.

Rheumatoid arthritis symptoms are unique because of symmetry: They affect joints on both sides of the body. This can include both hands, both knees, and so on. Rheumatoid arthritis is a chronic condition. Once diagnosed, it persists for life.

Patients experience different symptoms based on what joints are affected and how the disease progresses. Read our disclaimer for details. Results First Posted : August 15, Last Update Posted : September 18, Study Description. The purpose of this study is to determine whether baricitinib is superior to placebo in the treatment of participants with moderately to severely active Rheumatoid Arthritis RA who have had an inadequate response to methotrexate MTX treatment.

MedlinePlus related topics: Arthritis Rheumatoid Arthritis. Drug Information available for: Methotrexate Adalimumab Baricitinib. FDA Resources. Arms and Interventions. Outcome Measures. Participants with missing responses and participants who discontinued study or drug or were rescued before analysis timepoint were deemed non-responders. The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty 0 [without any difficulty], 1 [with some difficulty], 2 [with much difficulty], and 3 [unable to do] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities.

Scores for each functional area were averaged to calculate the HAQ-DI score, which ranged from 0 no disability to 3 worst disability. Scores ranged 1. The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 scored with higher scores indicating higher disease activity , SJC28 scored with higher scores indicating higher disease activity , Patient's Global Assessment of Disease Activity scored on a visual analogue scale from cm with higher scores indicating higher disease activity , and Physician's Global Assessment of Disease Activity scored on a visual analogue scale from cm with higher scores indicating higher disease activity.

The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. A negative change from baseline indicates improvement in condition.

The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity. Participants recorded the duration of their morning joint stiffness MJS in hours and minutes into electronic diaries daily. If morning joint stiffness duration was longer than 12 hours minutes , it was truncated to minutes for statistical presentations and analyses.

The average value across the 7 days preceding each visit was calculated. A decrease in duration of morning joint stiffness indicated an improvement in the participant's condition. Participants rated the severity of their morning joint stiffness by selecting a number from 0 to 10 that best described their overall level of morning joint stiffness from the time they woke up, where 0 represents "no joint stiffness" and 10 represents "joint stiffness as bad as you can imagine".

Participants reported their severity daily in electronic diaries. Participants rated their tiredness by selecting a number from 0 to 10 that best described their worst tiredness during the last 24 hours, where 0 represents "no tiredness" and 10 represents "as bad as you can imagine". Participants reported their worst tiredness in electronic diaries. The average value across the 7 days preceding each visit is calculated.

Participants rated their joint pain by selecting a number from 0 to 10 that best described their worst joint pain during the last 24 hours, where 0 represents "no pain" and 10 represents "pain as bad as you can imagine". Clinical trials are a crucial catalyst between disease research and the availability of treatment options. The findings of clinical trials lead to scientific discoveries about how to not only effectively treat the disease, but often how to diagnose and prevent the disease altogether.

Patients who participate in clinical trials report that they feel their participation is contributing to the positive advancement of science and clinical practice. Clinical trials offer support and hope to patients and their families as well as others around the world who may need treatment in the future. Because RA has no known exact cause and no known cure, clinical trials are extremely important in helping to better understand the disease.

RA clinical trials discover new information about the underlying disease process, as well as how to better diagnose it and how it progresses. New treatments are currently being tested that focus on advanced types of disease-modifying antirheumatic drugs DMARDs including immunotherapies and biological response modifiers. RA clinical trials are available to select RA patients. To find out about the available clinical trials, you must first discuss the opportunities with your physician.

Your physician can discuss with you disease registries that you qualify for as well as refer you to ongoing clinical trials that you can be a part of. Being part of a clinical trial can be a rewarding and fulfilling experience that helps with indispensable scientific discoveries. If you are considering participating in a clinical trial, there are some important things to know before you proceed.

Below are some things to consider and understand before participating in a RA or any clinical trial:. Participating in clinical trials gives you the chance to receive additional medical attention and support. Group A Streptococcal Infections. Vaccine Research. Types of Group A Strep. Vaccine Development. Basic Research. Leprosy Hansen's Disease. Lyme Disease. Antibiotic Treatment. Chronic Lyme Disease. Featured Research. Types of PIDDs.

Talking to Your Doctor. Therapeutic Approaches. Animal Prion Diseases and Humans. Rocky Mountain Spotted Fever. Schistosomiasis Bilharzia. Tickborne Diseases. Tuberculosis Drugs. West Nile Virus. Addressing Zika Virus. Types of Funding Opportunities. See Funded Projects. Sample Applications. Determine Eligibility. Prepare Your Application. Additional Application Elements.

Research with Special Considerations. Submit an Application. Track Your Application. Understand the Review Process.